FDA neuroscience chief Billy Dunn, who led Aduhelm approval, will leave agency
The FDA’s top neuroscience expert Billy Dunn, who was embroiled in controversy over his close ties with industry ahead of two key Alzheimer’s drug approvals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
